{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T03:07:40Z","timestamp":1793156860648,"version":"4.5.0"},"reference-count":38,"publisher":"American Medical Association (AMA)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"\n Importance<\/jats:title>\n Prenatal opioid exposure (POE) may alter with fetal development of the immune system, which may influence long-term health and susceptibility to immune-related conditions.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To compare the risk of hospitalization and emergency department presentation for immune-related conditions in children with and without POE.<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n This retrospective, population-based cohort study used linked administrative health records of all children born in Western Australia between January 1, 2003, and December 31, 2018 (N\u2009=\u2009401\u202f462).<\/jats:p>\n <\/jats:sec>\n \n Exposure<\/jats:title>\n Prenatal exposure to prescription opioids (overall and by trimester), neonatal abstinence syndrome diagnosis, and opioid indication (pain or opioid use disorder [OUD]).<\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n The main outcome was hospital admissions and emergency department presentations during which a child was diagnosed with an immune-related condition, including infections, conditions associated with an overactive immune system (eg, asthma, eczema, and allergy and anaphylaxis), and autoimmune diseases diagnosed before age 5 years or June 30, 2020. Data were analyzed between August 30, 2022, and February 27, 2023.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n Neonates with POE (1656 [0.4%]; mean [SD] gestational age, 37.7 [2.1] weeks; 836 females [50.5%]; 820 males [49.5%]) were more likely to be born preterm, have low birth weight for gestational age, and be coexposed to cigarette smoke compared with nonexposed neonates. Perinatal opioid exposure was associated with an increased risk of perinatal infection (adjusted odds ratio [AOR], 1.62; 95% CI, 1.38-1.90) and eczema and dermatitis (AOR, 11.91; 95% CI, 9.84-14.41) compared with nonexposure. Neonatal abstinence syndrome was also associated with both conditions (AOR, 2.91 [95% CI, 2.36-3.57] and 31.11 [95% CI, 24.64-39.28], respectively). Prenatal opioid exposure was also associated with an increased risk of childhood asthma (adjusted hazard ratio [AHR], 1.44; 95% CI, 1.16-1.79), but not allergies and anaphylaxis. It was also associated with an increased risk of childhood eczema and dermatitis, but only in children with POE from opioids used to treat OUD (AHR, 1.47; 95% CI, 1.08-1.99) rather than pain. In contrast, POE from opioids used for pain was associated with an increased risk of infection (AHR, 1.44; 95% CI, 1.32-1.58), but POE to opioids used to treat OUD was not. Autoimmune conditions were rare and were not observed to be associated with POE.<\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n In this cohort study, POE was associated with an increased risk of infection, eczema and dermatitis, and asthma, but not allergies and anaphylaxis or autoimmune conditions. These findings highlight the importance of further study of opioid-induced immune changes during pregnancy, the potential impact on long-term health in exposed children, and the mechanisms of opioid-induced immune dysregulation.<\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2023.51933","type":"journal-article","created":{"date-parts":[[2024,1,17]],"date-time":"2024-01-17T12:51:10Z","timestamp":1705495870000},"page":"e2351933","source":"Crossref","is-referenced-by-count":27,"title":["Prenatal Opioid Exposure and Immune-Related Conditions in Children"],"prefix":"10.1001","volume":"7","author":[{"given":"Erin","family":"Kelty","sequence":"first","affiliation":[{"name":"School of Population and Global Health, The University of Western Australia, Crawley, Western Australia, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaitlyn","family":"Rae","sequence":"additional","affiliation":[{"name":"School of Human Sciences, The University of Western Australia, Crawley, Western Australia, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren L.","family":"Jantzie","sequence":"additional","affiliation":[{"name":"Division of Neonatal-Perinatal Medicine, Department of Pediatrics, Johns Hopkins University School of Medicine, Baltimore, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caitlin S.","family":"Wyrwoll","sequence":"additional","affiliation":[{"name":"School of Human Sciences, The University of Western Australia, Crawley, Western Australia, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David B.","family":"Preen","sequence":"additional","affiliation":[{"name":"School of Population and Global Health, The University of Western Australia, Crawley, Western Australia, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2024,1,17]]},"reference":[{"issue":"2","key":"zoi231523r1","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/S0006-8993(99)01753-9","article-title":"Opioid growth factor and organ development in rat and human embryos.","volume":"839","author":"Zagon","year":"1999","journal-title":"Brain Res"},{"issue":"1","key":"zoi231523r2","first-page":"129","article-title":"Opioid modulation of the fetal hypothalamic-pituitary-adrenal axis: the role of receptor subtypes and route of administration.","volume":"281","author":"Taylor","year":"1997","journal-title":"J Pharmacol Exp Ther"},{"issue":"24","key":"zoi231523r3","doi-asserted-by":"publisher","first-page":"2449","DOI":"10.1016\/0024-3205(83)90639-2","article-title":"Naltrexone modulates growth in infant rats.","volume":"33","author":"Zagon","year":"1983","journal-title":"Life Sci"},{"key":"zoi231523r4","doi-asserted-by":"publisher","DOI":"10.1016\/j.earlhumdev.2020.105188","article-title":"Prenatal opioid exposure\u2013increasing evidence of harm.","volume":"150","author":"Mactier","year":"2020","journal-title":"Early Hum Dev"},{"issue":"3","key":"zoi231523r5","doi-asserted-by":"publisher","first-page":"430","DOI":"10.4103\/1673-5374.293136","article-title":"Neonatal opioid exposure: public health crisis and novel neuroinflammatory disease.","volume":"16","author":"Vasan","year":"2021","journal-title":"Neural Regen Res"},{"key":"zoi231523r6","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.bbi.2019.11.007","article-title":"Prenatal opioid exposure: the next neonatal neuroinflammatory disease.","volume":"84","author":"Jantzie","year":"2020","journal-title":"Brain Behav Immun"},{"key":"zoi231523r7","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2023.1140400","article-title":"A review of the genomics of neonatal abstinence syndrome.","volume":"14","author":"Yen","year":"2023","journal-title":"Front Genet"},{"key":"zoi231523r8","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.jpeds.2019.07.032","article-title":"Sex-dependent gene expression in infants with neonatal opioid withdrawal syndrome.","volume":"214","author":"Yen","year":"2019","journal-title":"J Pediatr"},{"key":"zoi231523r9","doi-asserted-by":"publisher","DOI":"10.3389\/fped.2022.1039055","article-title":"The immediate and long-term effects of prenatal opioid exposure.","volume":"10","author":"Yen","year":"2022","journal-title":"Front Pediatr"},{"key":"zoi231523r10","doi-asserted-by":"publisher","DOI":"10.3389\/fped.2021.805763","article-title":"Aberrant feeding and growth in neonates with prenatal opioid exposure: evidence of neuromodulation and behavioral changes.","volume":"9","author":"Yen","year":"2022","journal-title":"Front Pediatr"},{"key":"zoi231523r11","doi-asserted-by":"publisher","first-page":"272","DOI":"10.3389\/fped.2020.00272","article-title":"Perinatal opioid exposure primes the peripheral immune system toward hyperreactivity.","volume":"8","author":"Newville","year":"2020","journal-title":"Front Pediatr"},{"issue":"6","key":"zoi231523r12","doi-asserted-by":"publisher","first-page":"1566","DOI":"10.1038\/s41390-022-02014-x","article-title":"The impact of opioid exposure during pregnancy on the human neonatal immune profile.","volume":"92","author":"Miller","year":"2022","journal-title":"Pediatr Res"},{"key":"zoi231523r13","doi-asserted-by":"publisher","first-page":"2904","DOI":"10.3389\/fimmu.2019.02904","article-title":"The role of opioid receptors in immune system function.","volume":"10","author":"Eisenstein","year":"2019","journal-title":"Front Immunol"},{"issue":"11","key":"zoi231523r14","doi-asserted-by":"publisher","first-page":"3315","DOI":"10.1007\/s11606-020-06155-9","article-title":"The association between prescribed opioid receipt and community-acquired pneumonia in adults: a systematic review and meta-analysis.","volume":"35","author":"Steffens","year":"2020","journal-title":"J Gen Intern Med"},{"issue":"14","key":"zoi231523r15","doi-asserted-by":"publisher","first-page":"2717","DOI":"10.1111\/bph.v175.14","article-title":"Opioids and the immune system\u2014friend or foe.","volume":"175","author":"Plein","year":"2018","journal-title":"Br J Pharmacol"},{"issue":"9","key":"zoi231523r16","doi-asserted-by":"publisher","first-page":"5221","DOI":"10.1128\/IAI.00208-06","article-title":"Morphine withdrawal lowers host defense to enteric bacteria: spontaneous sepsis and increased sensitivity to oral Salmonella enterica serovar Typhimurium infection.","volume":"74","author":"Feng","year":"2006","journal-title":"Infect Immun"},{"issue":"1-2","key":"zoi231523r17","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.jneuroim.2005.03.017","article-title":"Morphine withdrawal sensitizes mice to lipopolysaccharide: elevated TNF-alpha and nitric oxide with decreased IL-12.","volume":"164","author":"Feng","year":"2005","journal-title":"J Neuroimmunol"},{"issue":"5","key":"zoi231523r18","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1002\/phar.v42.5","article-title":"Contribution of pharmaceutical drugs of dependence to the incidence of neonatal abstinence syndrome in Western Australia between 2003 and 2018.","volume":"42","author":"Kelty","year":"2022","journal-title":"Pharmacotherapy"},{"key":"zoi231523r19","first-page":"483","article-title":"Workshop to identify critical windows of exposure for children\u2019s health: immune and respiratory systems work group summary.","volume":"108","author":"Dietert","year":"2000","journal-title":"Environ Health Perspect"},{"issue":"1","key":"zoi231523r21","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1136\/archdischild-2017-314628","article-title":"Maternal weight and infections in early childhood: a cohort study.","volume":"104","author":"Videholm","year":"2019","journal-title":"Arch Dis Child"},{"issue":"1-3","key":"zoi231523r22","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1007\/s12026-009-8153-2","article-title":"The prevalence of 30 ICD-10 autoimmune diseases in Denmark.","volume":"47","author":"Eaton","year":"2010","journal-title":"Immunol Res"},{"issue":"3","key":"zoi231523r23","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/j.jaac.2016.12.010","article-title":"Associations between autoimmune diseases and attention-deficit\/hyperactivity disorder: a nationwide study.","volume":"56","author":"Nielsen","year":"2017","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"issue":"23","key":"zoi231523r24","doi-asserted-by":"publisher","first-page":"2388","DOI":"10.1001\/jama.2018.7028","article-title":"Association of stress-related disorders with subsequent autoimmune disease.","volume":"319","author":"Song","year":"2018","journal-title":"JAMA"},{"issue":"4","key":"zoi231523r25","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1003963","article-title":"Prenatal influenza vaccination and allergic and autoimmune diseases in childhood: a longitudinal, population-based linked cohort study.","volume":"19","author":"Foo","year":"2022","journal-title":"PLoS Med"},{"issue":"2","key":"zoi231523r26","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2020.37388","article-title":"Prevalence of prenatal opioid exposure in Ontario, Canada, 2014-2019.","volume":"4","author":"Camden","year":"2021","journal-title":"JAMA Netw Open"},{"issue":"5","key":"zoi231523r27","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1097\/ALN.0000000000000172","article-title":"Patterns of opioid utilization in pregnancy in a large cohort of commercial insurance beneficiaries in the United States.","volume":"120","author":"Bateman","year":"2014","journal-title":"Anesthesiology"},{"issue":"2","key":"zoi231523r28","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1001\/jama.2020.24991","article-title":"Neonatal abstinence syndrome and maternal opioid-related diagnoses in the US, 2010-2017.","volume":"325","author":"Hirai","year":"2021","journal-title":"JAMA"},{"key":"zoi231523r29","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/j.drugalcdep.2017.12.019","article-title":"Trends in incidence of neonatal abstinence syndrome in Canada and associated healthcare resource utilization.","volume":"185","author":"Filteau","year":"2018","journal-title":"Drug Alcohol Depend"},{"issue":"1","key":"zoi231523r30","doi-asserted-by":"publisher","first-page":"F26","DOI":"10.1136\/archdischild-2015-308948","article-title":"Neonatal drug withdrawal syndrome: cross-country comparison using hospital administrative data in England, the USA, Western Australia and Ontario, Canada.","volume":"101","author":"Davies","year":"2016","journal-title":"Arch Dis Child Fetal Neonatal Ed"},{"key":"zoi231523r31","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.pedn.2021.03.011","article-title":"Diagnoses during the first three years of life for children with prenatal opioid exposure and neonatal abstinence syndrome using a large maternal infant data hub.","volume":"61","author":"Arter","year":"2021","journal-title":"J Pediatr Nurs"},{"issue":"1","key":"zoi231523r32","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1097\/ANC.0000000000000898","article-title":"Designing and implementing a skin care protocol for infants with neonatal abstinence syndrome to decrease rates of diaper dermatitis.","volume":"22","author":"Glashan","year":"2022","journal-title":"Adv Neonatal Care"},{"issue":"2","key":"zoi231523r33","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1159\/000082563","article-title":"Changes of epidermal mu-opiate receptor expression and nerve endings in chronic atopic dermatitis.","volume":"210","author":"Bigliardi-Qi","year":"2005","journal-title":"Dermatology"},{"issue":"9","key":"zoi231523r34","doi-asserted-by":"publisher","first-page":"2228","DOI":"10.1038\/sj.jid.5700942","article-title":"Possible roles of epidermal opioid systems in pruritus of atopic dermatitis.","volume":"127","author":"Tominaga","year":"2007","journal-title":"J Invest Dermatol"},{"issue":"5","key":"zoi231523r35","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01090-2018","article-title":"Prescribed analgesics in pregnancy and risk of childhood asthma.","volume":"53","author":"Shaheen","year":"2019","journal-title":"Eur Respir J"},{"issue":"1","key":"zoi231523r36","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.jaci.2003.10.041","article-title":"Distinguishing severe asthma phenotypes: role of age at onset and eosinophilic inflammation.","volume":"113","author":"Miranda","year":"2004","journal-title":"J Allergy Clin Immunol"},{"issue":"11","key":"zoi231523r37","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1007\/s40265-017-0762-9","article-title":"A retrospective cohort study of obstetric outcomes in opioid-dependent women treated with implant naltrexone, oral methadone or sublingual buprenorphine, and non-dependent controls.","volume":"77","author":"Kelty","year":"2017","journal-title":"Drugs"},{"issue":"6","key":"zoi231523r38","first-page":"E623","article-title":"Association between socio-demographic and health functioning variables among patients with opioid use disorder introduced by prescription: a prospective cohort study.","volume":"21","author":"Sanger","year":"2018","journal-title":"Pain Physician"},{"key":"zoi231523r20","volume-title":"National Statement on Ethical Conduct in Human Research","author":"National Health and Medical Research Council","year":"2018"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2814019\/kelty_2024_oi_231523_1704751059.72452.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,17]],"date-time":"2024-01-17T12:51:15Z","timestamp":1705495875000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2814019"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,17]]},"references-count":38,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1,2]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2023.51933","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,17]]}}}